NEOGENOMICS INC (NEO)
Health Care · cancer diagnostics · NASDAQ
NeoGenomics is a leading provider of oncology diagnostic solutions that empower clinicians and patients with actionable insights to guide personalized cancer care.
What NEOGENOMICS INC does
NeoGenomics provides a comprehensive range of oncology diagnostic testing and consultative services for community-based pathology and oncology practices, hospitals, and pharmaceutical companies. The company operates a network of CAP-accredited and CLIA-certified laboratories in the US and the UK, offering specialized testing including cytogenetics, FISH, flow cytometry, immunohistochemistry, and next-generation sequencing. Their services focus on delivering actionable insights to guide cancer treatment decisions across the clinical care continuum.
Recent developments
In October 2026, the company announced a leadership transition where President and COO Warren Stone will become CEO on January 4, 2027, succeeding Tony Zook, who will become Executive Chairman. For Q3 2026, the company expects revenue of approximately $209 million, with 28% NGS revenue growth, and plans to raise its full-year total revenue guidance.
From NEOGENOMICS INC's filing of 2026-10-05.
Themes: precision medicine, oncology diagnostics, next-generation sequencing, molecular diagnostics, cancer research support, digital pathology
Fundamentals
- Price$16.02 as of 2026-10-08 close
- Market cap$2.1B as of 2026-07-24 (share count; price 2026-10-08)
- 1-year return+74.7% 2025-10-08 close $9.17 → 2026-10-08 close $16.02
- P/En/a negative earnings
- ROE-12.9% FY2025, SEC XBRL
- Debt / equity0.48 as of 2026-09-03
- Revenue growth (YoY)+11.2% as of 2026-09-03
- Beta1.18 as of 2026-09-03
- Last reported earnings2026-10-05 SEC EDGAR Form 8-K (Item 2.02)
How NEO compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NEO is not currently in any published Top 10 list. Its scores are below.
Top 10 score
45.6 #971 of 1,379 scored · #119 of 151 in Health Care
Trend 60th (trading above its 200-day average) and growth 59th (revenue growth year over year 11.2%); weakest is profitability (9th, return on equity -12.9%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How NEOGENOMICS INC looks technically
NEOGENOMICS INC (NEO) is trading 29.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 68 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 20.5% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 29.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +29.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.44 | $17.44 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.42 | $12.42 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 68 trading days ago — a "golden cross", a bullish long-term signal | 68 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control | 34.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 37.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($15.41 to $20.15) — its "stochastic" reading is 13 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 12.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $20.15 | $20.15 |
|---|---|---|
| From the 52-week high | it is 20.5% below its 52-week high (its highest price of the past year) | -20.5% |
| Above the 52-week low | it is 126.6% above its 52-week low (its lowest price of the past year) | +126.6% |
| Below the 52-week high | it is 20.5% below its highest point of the past year | 20.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 15 trading days ago | 15 sessions |
| All-time high | its highest closing price on record is $61.57 (set on 2021-02-16) | $61.57 |
| Given back of the 52-week move | over the past year its closes ranged ($7.19 to $19.91), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.64 to $12.05. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.6% |
| From the all-time high | it is 74.0% below its all-time high | -74.0% |
| Nearest price level | it is trading 2.3% above a support level at $15.64 — a price it turned at twice since 2026-07-06, most recently on 2026-08-17. Since 2024-10-08 it has 15 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.3% |
| All-time low | its lowest closing price on record is $0.12 (set on 2006-01-18) | $0.12 |
| Above the all-time low | it is 13250.0% above its all-time low | +13,250% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 65th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.01 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.01 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $16.15 and $20.76 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $16.15 – $18.46 – $20.76 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 3.6 daily ranges above its 200-day average price (29.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.55× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.6% |
|---|---|---|
| Open gap | it gapped 16.5% above the previous close 50 sessions ago and has not traded back through the level it left behind at 13.4 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +16.5% |
| Gap filled | a 4.6% gap up opened on 2026-10-06 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.8 percentage points (the stock lost 8.8% while the market gained 1.0%) | -9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 8.7 percentage points (the stock gained 12.5% while the market gained 3.8%) | +8.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 82.3 percentage points (the stock gained 99.8% while the market gained 17.5%) | +82.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 59.7 percentage points (the stock gained 74.7% while the market gained 15.0%) | +59.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 13.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 26% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $12.69 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | +26.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-07-28 (its 10-Q), so the typical buyer over that stretch is under water. That average is $17.25 — a volume-weighted average of daily closes over 52 sessions, not a true tick-by-tick VWAP. | -7.2% |
Price levels it has turned at before
NEO last closed at $16.02 on 2026-10-08. Since 2024-10-08 it has turned at 15 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.64 | Support | 2.3% below the last close | turned there twice · 2026-07-06 to 2026-08-17 |
| $16.89 | Resistance | 5.5% above the last close | turned there twice · 2026-08-10 to 2026-09-04 |
| $14.77 | Support | 7.8% below the last close | turned there twice · 2024-11-19 to 2025-02-14 |
| $13.77 | Support | 14.0% below the last close | turned there twice · 2026-01-12 to 2026-07-14 |
| $19.05 | Resistance | 18.9% above the last close | turned there twice · 2024-12-10 to 2025-01-08 |
| $19.91 | Resistance | 24.3% above the last close | turned there twice · 2026-08-27 to 2026-09-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · beating the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$19.72 range $16.00 – $35.00; median $19.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NEO
- Consensus EPS estimate$0.05364 next reporting period, as of 2026-10-04
- Estimate change, 30 days+$0.00164 from $0.052, on 2026-08-29, 36-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Subject to complex regulatory oversight including CLIA and CAP accreditation requirements.","Operating results may fluctuate due to evolving healthcare reimbursement policies and payor practices.","Business success relies on the ability to innovate and integrate new diagnostic technologies such as NGS."]
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 1 sell ($321400) — 1 selling insider
- Last 180 days · read to 2026-10-040 buys · 3 sells ($440224) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NEO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for NEO from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding NEO as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 26,679,296
- Reported value $389,250,933
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 2 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NEO's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NEO had 16,709,463 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NEO had 13.0% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.18 days to cover at the same settlement.
- Reported short interest (shares) 16,709,463
- Short interest (% of shares outstanding) 13.0%
- Prior settlement (shares) 15,759,505
- Reported change 6.03%
- Days to cover (reported) 11.18
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Quest Diagnostics (DGX)
- LabCorp (LH)
- Guardant Health (GH)
- Exact Sciences (EXAS)
- Foundation Medicine (Roche)
- Caris Life Sciences
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NEO vs…
NEOGENOMICS INC is found in…
Frequently asked questions
What does NEOGENOMICS INC (NEO) do?
NeoGenomics provides a comprehensive range of oncology diagnostic testing and consultative services for community-based pathology and oncology practices, hospitals, and pharmaceutical companies. The company operates a network of CAP-accredited and CLIA-certified laboratories in the US and the UK, offering specialized testing including cytogenetics, FISH, flow cytometry, immunohistochemistry, and next-generation sequencing.
What sector is NEOGENOMICS INC (NEO) in?
NEOGENOMICS INC (NEO) is classified in the Health Care sector. Its industry is cancer diagnostics. It trades on NASDAQ.
Who are NEOGENOMICS INC's (NEO) competitors?
Notable peers of NEOGENOMICS INC (NEO) include Quest Diagnostics, LabCorp, Guardant Health, Exact Sciences and Foundation Medicine (Roche). This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in NEO?
Yes — we hold 2 matched STOCK Act disclosures for NEO from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is NEOGENOMICS INC (NEO) overbought or oversold right now?
NEOGENOMICS INC (NEO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NEO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.